How to Find and Evaluate a Clinical Trial for COPD
When a research team in Melbourne, Australia finished the first dosing cohort of an ongoing COPD study earlier this year, the only thing confirmed was safety. The cohort completed its protocol-specified 28-day monitoring period with no therapy-related adverse events, and the study moved on to the next dose level. That is what a clinical trial actually produces at this stage: safety data, not a treatment you can ask your doctor for. If you or someone you care for has COPD and you're wondering whether a trial might be worth pursuing, the practical work starts with your own records, moves through a public registry, and ends with a direct conversation with a study team. None of it requires guessing.
What You Need Before You Start Searching
Before you open a registry, gather four things: your COPD diagnosis documentation, your most recent spirometry results including your FEV1 value, your smoking history in pack-years, and a current list of your medications. Many sponsor-run COPD trials set eligibility around an age range of 40 to 80 and a smoking history of more than 10 pack-years, so having those numbers on hand lets you screen yourself against a study record in minutes instead of guessing. Your medication list matters just as much. Some trials require that you've already been on standard triple therapy, meaning three inhaled medicines used together, for a set period before you can join. Others want participants who haven't started maintenance treatment yet. Knowing where you stand on that spectrum before you search saves you from reading through pages of criteria only to find you're excluded on the first line.
Search ClinicalTrials.gov for a COPD Trial
ClinicalTrials.gov is the main U.S. registry for locating COPD studies, and at any given time it lists dozens of active trials. One recent count put the number at 31 active COPD clinical trials seeking participants, concentrated heavily in Florida, California, Texas, and South Carolina. Every study on the registry carries a unique identifier called an NCT number, which you'll use to pull up the full record, including eligibility criteria and site locations.
Set Your Filters and Run the Search
Enter "COPD" as your condition term, then narrow the results using the recruitment status, age range, and location filters on the search page. This produces a ranked list of study records you can sort by distance, which matters if you want a site close enough to manage repeat visits. Each result links to a full record under its own NCT number. For example, a solrikitug study registered as NCT06496620 is a randomized, double-blind, placebo-controlled trial testing dosing in COPD patients ages 40 to 75. Other named studies you'll run across in a typical search carry their own numbers, such as NCT06283966 and NCT06883305, and each one has its own eligibility page, visit schedule, and location list attached to that identifier.
Read a Study Record's Eligibility Criteria
Eligibility criteria vary meaningfully even between trials studying similar drug classes. The UPLIFT trial, which enrolled around 6,000 patients to study tiotropium's effect on FEV1 decline, required participants to be at least 40 years old with an FEV1 of 70% or less after bronchodilation and an FEV1 to FVC ratio of 70% or less. The WISDOM trial, by comparison, enrolled only patients with severe or very severe COPD, defined by an FEV1 under 50%. That's a wide gap, and it means a reader with moderate COPD could qualify for one study design and not another built around a stricter severity cutoff. Outside these landmark trials, many current sponsor-run studies set more general criteria: age 40 to 80, more than 10 pack-years of smoking history, and a confirmed COPD diagnosis for at least a year with a history of flare-ups. Read the full inclusion and exclusion list on the record itself rather than relying on a summary, since a single line about prior medication use or a recent hospitalization can rule a candidate in or out.
Decode Status Labels Like Recruiting and Active Not Recruiting
Every study record carries a status label, and it changes what you can do next. "Recruiting" means the study is actively accepting new participants. "Active, not recruiting" means the study is still running, but enrollment has closed, so there's nothing to apply for even if the location and criteria look like a match. A separate distinction worth understanding is whether a listed study is interventional or observational. An interventional trial tests a treatment. An observational study, like SPIROMICS SOURCE, simply tracks disease progression, in that case following 1,000 participants ages 30 to 55 to better define early COPD in younger, at-risk individuals, without testing any drug or device. Checking both the status label and the study type before you contact anyone saves a wasted call.
Understand What a Trial Actually Involves Before You Commit
A clinical trial is a research study testing new approaches to prevent, screen for, diagnose, or treat a disease. As the American Lung Association puts it, Each study answers scientific questions and tries to find better ways to prevent, screen for, diagnose or treat a disease. Many COPD drug trials use a randomized, double-blind, placebo-controlled design, which means neither you nor your care team knows whether you're receiving the study medicine or a placebo until the trial ends. The odds depend on the phase. In one current Phase 2 COPD trial, participants have a 67% chance of receiving the active medicine and a 33% chance of receiving a placebo; in Phase 3 of that same program, the split is 50/50. Before any of that starts, a study physician confirms your eligibility, you sign an informed consent document explaining the risks and procedures, and only then do screening tests begin. It's worth knowing that several landmark COPD trials, including TORCH, UPLIFT, WISDOM, and TIOSPIR, found no statistically significant difference on their primary mortality or lung-function endpoints, even when they showed benefits elsewhere, such as TORCH's reduction in exacerbation rate. A trial testing a new approach doesn't guarantee that approach will outperform existing care on every measure it set out to test.
Ask the Study Team These Questions Before You Enroll
Once you've found a record that looks like a match, a phone call or intake visit with the study team is where the real evaluation happens. Bring these questions:
What phase is this trial in, and what are the actual odds of receiving the study medicine versus a placebo?
Can I withdraw at any point, and will that affect my regular medical care? Participants in comparable COPD trials are told they're free to stop at any time for any reason without it affecting their standard care or benefits.
What does the visit schedule look like, and how many total appointments should I expect?
Is the study medicine and are the study-related procedures provided at no cost, and do I need health insurance to take part? In several current trials, the study medicine and procedures are covered at no cost, and participants don't need health insurance to take part.
What happens between now and enrollment? A typical sequence runs from an initial consultation, to an eligibility review by the study physician, to signing informed consent, to screening tests, and only then to enrollment itself.
Weigh Compensation, Cost, and Logistics
Time commitment varies widely by study design. A shorter trial might involve around 9 visits total. A longer biologic trial can run about 68 weeks, roughly 16 months, with up to 18 appointments across that period. Compensation also varies: one current program lists compensation up to $1,300 for a completed study. In current COPD trials, study medicine and study-related procedures are typically covered at no cost, and participants generally don't need health insurance to take part. That combination, no cost plus defined compensation, is worth weighing against the actual number of visits and the distance you'd need to travel for each one, since a trial with generous compensation but 18 appointments over a year and a half is a very different commitment than one with 9 visits and a shorter timeline.
See How a Registered Study Like SMSbiotech's COPD Program Fits the Picture
SMSbiotech's ongoing Phase 1b trial in Melbourne, Australia is a concrete example of what a registered, early-stage COPD study looks like in practice. The trial is evaluating nebulized SMS Cells in ascending-dose cohorts. The first cohort finished the 28-day safety monitoring window set by the study protocol with no adverse events attributed to the therapy, and dosing has now escalated to the second of three planned cohorts. Separately, the U.S. FDA has cleared SMSbiotech's Investigational New Drug application for this program, issuing a "Study May Proceed" notification that allows the company to begin a distinct U.S. Phase 1b study, with first patient dosing targeted for the fourth quarter of 2026. That FDA clearance of the IND for SMSbiotech's COPD program confirms regulatory permission to start the U.S. arm; it says nothing yet about whether the therapy works. SMSbiotech has separately described the patented stem-cell technology designed to treat COPD behind SMS Cells and presented data on the regenerative mechanism in human COPD patients at industry meetings, but that background research doesn't change what the Phase 1b trial itself has reported so far. SMS Cells remain investigational. They are not an approved treatment for COPD, and nothing here implies that any particular patient would be eligible for this or any other trial, or that participation would produce a treatment benefit. The value of walking through a record like this one is procedural: it shows what a Phase 1b safety trial actually reports at this stage, cohort completion and adverse event data, rather than efficacy claims.
Know When You've Found a Trial Worth Pursuing
You're ready to contact a study team once your own eligibility documents line up against the specific criteria written on that study's record, and once the location and visit schedule realistically fit your life. That means checking your FEV1 value, your pack-year history, and your medication list against the record itself. One more thing worth knowing before you commit: participation has a defined end. In studies with a set follow-up period, that often means a follow-up call about a month after your final clinic visit, closing out your involvement even after active treatment ends. More than 6,900 participants have taken part in studies run by the American Lung Association's own research network, the ACRC, across the U.S., so matching your records to a study, asking the right questions, and understanding what happens after the last visit is a well-established path. Once your documents match a record's criteria and the logistics work for you, you have enough information to make that first call.
References
"Clinical Trials for COPD | American Lung Association." lung.org, https://www.lung.org/lung-health-diseases/lung-disease-lookup/copd/treating/clinical-trials-for-copd.
"A Review of Clinical Trials That Contributed to Chronic Obstructive Pulmonary Disease Treatment Protocols - PMC." pmc.ncbi.nlm.nih.gov, https://pmc.ncbi.nlm.nih.gov/articles/PMC8140054/.
"UCSF Chronic Obstructive Pulmonary Disease Clinical Trials for 2026 — San Francisco Bay Area." clinicaltrials.ucsf.edu, https://clinicaltrials.ucsf.edu/chronic-obstructive-pulmonary-disease.
"COPD clinical trial C4531031| Pfizer." pfizerclinicaltrials.com, https://www.pfizerclinicaltrials.com/nct07363694-chronic-obstructive-pulmonary-disease-trial.
"COPD Clinical Trials | Enroll in a Lung Disease Study." crwf.com, https://www.crwf.com/clinical-studies/copd/.
"COPD Clinical Trials & Research Studies Near You (Updated 4/25)." policylab.us, https://policylab.us/clinical-trials/l/conditions/copd.
When a research team in Melbourne, Australia finished the first dosing cohort of an ongoing COPD study earlier this year, the only thing confirmed was safety. The cohort completed its protocol-specified 28-day monitoring period with no therapy-related adverse events, and the study moved on to the next dose level. That is what a clinical trial actually produces at this stage: safety data, not a treatment you can ask your doctor for. If you or someone you care for has COPD and you're wondering whether a trial might be worth pursuing, the practical work starts with your own records, moves through a public registry, and ends with a direct conversation with a study team. None of it requires guessing.
What You Need Before You Start Searching
Before you open a registry, gather four things: your COPD diagnosis documentation, your most recent spirometry results including your FEV1 value, your smoking history in pack-years, and a current list of your medications. Many sponsor-run COPD trials set eligibility around an age range of 40 to 80 and a smoking history of more than 10 pack-years, so having those numbers on hand lets you screen yourself against a study record in minutes instead of guessing. Your medication list matters just as much. Some trials require that you've already been on standard triple therapy, meaning three inhaled medicines used together, for a set period before you can join. Others want participants who haven't started maintenance treatment yet. Knowing where you stand on that spectrum before you search saves you from reading through pages of criteria only to find you're excluded on the first line.
Search ClinicalTrials.gov for a COPD Trial
ClinicalTrials.gov is the main U.S. registry for locating COPD studies, and at any given time it lists dozens of active trials. One recent count put the number at 31 active COPD clinical trials seeking participants, concentrated heavily in Florida, California, Texas, and South Carolina. Every study on the registry carries a unique identifier called an NCT number, which you'll use to pull up the full record, including eligibility criteria and site locations.
Set Your Filters and Run the Search
Enter "COPD" as your condition term, then narrow the results using the recruitment status, age range, and location filters on the search page. This produces a ranked list of study records you can sort by distance, which matters if you want a site close enough to manage repeat visits. Each result links to a full record under its own NCT number. For example, a solrikitug study registered as NCT06496620 is a randomized, double-blind, placebo-controlled trial testing dosing in COPD patients ages 40 to 75. Other named studies you'll run across in a typical search carry their own numbers, such as NCT06283966 and NCT06883305, and each one has its own eligibility page, visit schedule, and location list attached to that identifier.
Read a Study Record's Eligibility Criteria
Eligibility criteria vary meaningfully even between trials studying similar drug classes. The UPLIFT trial, which enrolled around 6,000 patients to study tiotropium's effect on FEV1 decline, required participants to be at least 40 years old with an FEV1 of 70% or less after bronchodilation and an FEV1 to FVC ratio of 70% or less. The WISDOM trial, by comparison, enrolled only patients with severe or very severe COPD, defined by an FEV1 under 50%. That's a wide gap, and it means a reader with moderate COPD could qualify for one study design and not another built around a stricter severity cutoff. Outside these landmark trials, many current sponsor-run studies set more general criteria: age 40 to 80, more than 10 pack-years of smoking history, and a confirmed COPD diagnosis for at least a year with a history of flare-ups. Read the full inclusion and exclusion list on the record itself rather than relying on a summary, since a single line about prior medication use or a recent hospitalization can rule a candidate in or out.
Decode Status Labels Like Recruiting and Active Not Recruiting
Every study record carries a status label, and it changes what you can do next. "Recruiting" means the study is actively accepting new participants. "Active, not recruiting" means the study is still running, but enrollment has closed, so there's nothing to apply for even if the location and criteria look like a match. A separate distinction worth understanding is whether a listed study is interventional or observational. An interventional trial tests a treatment. An observational study, like SPIROMICS SOURCE, simply tracks disease progression, in that case following 1,000 participants ages 30 to 55 to better define early COPD in younger, at-risk individuals, without testing any drug or device. Checking both the status label and the study type before you contact anyone saves a wasted call.
Understand What a Trial Actually Involves Before You Commit
A clinical trial is a research study testing new approaches to prevent, screen for, diagnose, or treat a disease. As the American Lung Association puts it, Each study answers scientific questions and tries to find better ways to prevent, screen for, diagnose or treat a disease. Many COPD drug trials use a randomized, double-blind, placebo-controlled design, which means neither you nor your care team knows whether you're receiving the study medicine or a placebo until the trial ends. The odds depend on the phase. In one current Phase 2 COPD trial, participants have a 67% chance of receiving the active medicine and a 33% chance of receiving a placebo; in Phase 3 of that same program, the split is 50/50. Before any of that starts, a study physician confirms your eligibility, you sign an informed consent document explaining the risks and procedures, and only then do screening tests begin. It's worth knowing that several landmark COPD trials, including TORCH, UPLIFT, WISDOM, and TIOSPIR, found no statistically significant difference on their primary mortality or lung-function endpoints, even when they showed benefits elsewhere, such as TORCH's reduction in exacerbation rate. A trial testing a new approach doesn't guarantee that approach will outperform existing care on every measure it set out to test.
Ask the Study Team These Questions Before You Enroll
Once you've found a record that looks like a match, a phone call or intake visit with the study team is where the real evaluation happens. Bring these questions:
What phase is this trial in, and what are the actual odds of receiving the study medicine versus a placebo?
Can I withdraw at any point, and will that affect my regular medical care? Participants in comparable COPD trials are told they're free to stop at any time for any reason without it affecting their standard care or benefits.
What does the visit schedule look like, and how many total appointments should I expect?
Is the study medicine and are the study-related procedures provided at no cost, and do I need health insurance to take part? In several current trials, the study medicine and procedures are covered at no cost, and participants don't need health insurance to take part.
What happens between now and enrollment? A typical sequence runs from an initial consultation, to an eligibility review by the study physician, to signing informed consent, to screening tests, and only then to enrollment itself.
Weigh Compensation, Cost, and Logistics
Time commitment varies widely by study design. A shorter trial might involve around 9 visits total. A longer biologic trial can run about 68 weeks, roughly 16 months, with up to 18 appointments across that period. Compensation also varies: one current program lists compensation up to $1,300 for a completed study. In current COPD trials, study medicine and study-related procedures are typically covered at no cost, and participants generally don't need health insurance to take part. That combination, no cost plus defined compensation, is worth weighing against the actual number of visits and the distance you'd need to travel for each one, since a trial with generous compensation but 18 appointments over a year and a half is a very different commitment than one with 9 visits and a shorter timeline.
See How a Registered Study Like SMSbiotech's COPD Program Fits the Picture
SMSbiotech's ongoing Phase 1b trial in Melbourne, Australia is a concrete example of what a registered, early-stage COPD study looks like in practice. The trial is evaluating nebulized SMS Cells in ascending-dose cohorts. The first cohort finished the 28-day safety monitoring window set by the study protocol with no adverse events attributed to the therapy, and dosing has now escalated to the second of three planned cohorts. Separately, the U.S. FDA has cleared SMSbiotech's Investigational New Drug application for this program, issuing a "Study May Proceed" notification that allows the company to begin a distinct U.S. Phase 1b study, with first patient dosing targeted for the fourth quarter of 2026. That FDA clearance of the IND for SMSbiotech's COPD program confirms regulatory permission to start the U.S. arm; it says nothing yet about whether the therapy works. SMSbiotech has separately described the patented stem-cell technology designed to treat COPD behind SMS Cells and presented data on the regenerative mechanism in human COPD patients at industry meetings, but that background research doesn't change what the Phase 1b trial itself has reported so far. SMS Cells remain investigational. They are not an approved treatment for COPD, and nothing here implies that any particular patient would be eligible for this or any other trial, or that participation would produce a treatment benefit. The value of walking through a record like this one is procedural: it shows what a Phase 1b safety trial actually reports at this stage, cohort completion and adverse event data, rather than efficacy claims.
Know When You've Found a Trial Worth Pursuing
You're ready to contact a study team once your own eligibility documents line up against the specific criteria written on that study's record, and once the location and visit schedule realistically fit your life. That means checking your FEV1 value, your pack-year history, and your medication list against the record itself. One more thing worth knowing before you commit: participation has a defined end. In studies with a set follow-up period, that often means a follow-up call about a month after your final clinic visit, closing out your involvement even after active treatment ends. More than 6,900 participants have taken part in studies run by the American Lung Association's own research network, the ACRC, across the U.S., so matching your records to a study, asking the right questions, and understanding what happens after the last visit is a well-established path. Once your documents match a record's criteria and the logistics work for you, you have enough information to make that first call.
References
"Clinical Trials for COPD | American Lung Association." lung.org, https://www.lung.org/lung-health-diseases/lung-disease-lookup/copd/treating/clinical-trials-for-copd.
"A Review of Clinical Trials That Contributed to Chronic Obstructive Pulmonary Disease Treatment Protocols - PMC." pmc.ncbi.nlm.nih.gov, https://pmc.ncbi.nlm.nih.gov/articles/PMC8140054/.
"UCSF Chronic Obstructive Pulmonary Disease Clinical Trials for 2026 — San Francisco Bay Area." clinicaltrials.ucsf.edu, https://clinicaltrials.ucsf.edu/chronic-obstructive-pulmonary-disease.
"COPD clinical trial C4531031| Pfizer." pfizerclinicaltrials.com, https://www.pfizerclinicaltrials.com/nct07363694-chronic-obstructive-pulmonary-disease-trial.
"COPD Clinical Trials | Enroll in a Lung Disease Study." crwf.com, https://www.crwf.com/clinical-studies/copd/.
"COPD Clinical Trials & Research Studies Near You (Updated 4/25)." policylab.us, https://policylab.us/clinical-trials/l/conditions/copd.
